Literature DB >> 25601446

Image-guided ablation of primary liver and renal tumours.

David J Breen1, Riccardo Lencioni2.   

Abstract

Image-guided ablation (IGA) techniques have evolved considerably over the past 20 years and are increasingly used to definitively treat small primary cancers of the liver and kidney. IGA is recommended by most guidelines as the best therapeutic choice for patients with early stage hepatocellular carcinoma (HCC)-defined as either a single tumour smaller than 5 cm or up to three nodules smaller than 3 cm-when surgical options are precluded, and has potential as first-line therapy, in lieu of surgery, for patients with very early stage tumours smaller than 2 cm. With regard to renal cell carcinoma, despite the absence of any randomized trial comparing the outcomes of IGA with those of standard partial nephrectomy, a growing amount of data demonstrate robust oncological outcomes for this minimally invasive approach and testify to its potential as a standard-of-care treatment. Herein, we review the various ablation techniques, the supporting evidence, and clinical application of IGA in the treatment of primary liver and kidney cancers.

Entities:  

Mesh:

Year:  2015        PMID: 25601446     DOI: 10.1038/nrclinonc.2014.237

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


  106 in total

1.  Percutaneous radiofrequency ablation does not affect glomerular filtration rate.

Authors:  Joseph A Pettus; David M Werle; Weston Saunders; Ashok Hemal; Andrew Karim Kader; David Childs; Ronald J Zagoria
Journal:  J Endourol       Date:  2010-10       Impact factor: 2.942

2.  Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  C Verslype; O Rosmorduc; P Rougier
Journal:  Ann Oncol       Date:  2012-10       Impact factor: 32.976

3.  Percutaneous cryoablation of renal masses >or=3 cm: efficacy and safety in treatment of 108 patients.

Authors:  Grant D Schmit; Thomas D Atwell; Matthew R Callstrom; Michael A Farrell; Bradley C Leibovich; David E Patterson; George K Chow; Michael L Blute; J William Charboneau
Journal:  J Endourol       Date:  2010-08       Impact factor: 2.942

4.  Rising incidence of small renal masses: a need to reassess treatment effect.

Authors:  John M Hollingsworth; David C Miller; Stephanie Daignault; Brent K Hollenbeck
Journal:  J Natl Cancer Inst       Date:  2006-09-20       Impact factor: 13.506

Review 5.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

6.  Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm.

Authors:  Shi-Ming Lin; Chun-Jung Lin; Chen-Chun Lin; Chao-Wei Hsu; Yi-Cheng Chen
Journal:  Gastroenterology       Date:  2004-12       Impact factor: 22.682

7.  Hepatic resection for hepatocellular carcinoma: do contemporary morbidity and mortality rates demand a transition to ablation as first-line treatment?

Authors:  George Z Li; Paul J Speicher; Michael E Lidsky; Marcus D Darrabie; John E Scarborough; Rebekah R White; Ryan S Turley; Bryan M Clary
Journal:  J Am Coll Surg       Date:  2014-01-10       Impact factor: 6.113

8.  The value of preoperative needle core biopsy for diagnosing benign lesions among small, incidentally detected renal masses.

Authors:  Beverley A Shannon; Ronald J Cohen; Hildemarie de Bruto; Robert J Davies
Journal:  J Urol       Date:  2008-08-15       Impact factor: 7.450

Review 9.  Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies.

Authors:  Yun Ku Cho; Jae Kyun Kim; Mi Young Kim; Hyunchul Rhim; Joon Koo Han
Journal:  Hepatology       Date:  2009-02       Impact factor: 17.425

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  21 in total

Review 1.  Microwave ablation of hepatocellular carcinoma.

Authors:  Guido Poggi; Nevio Tosoratti; Benedetta Montagna; Chiara Picchi
Journal:  World J Hepatol       Date:  2015-11-08

Review 2.  RFA plus lyso-thermosensitive liposomal doxorubicin: in search of the optimal approach to cure intermediate-size hepatocellular carcinoma.

Authors:  Riccardo Lencioni; Dania Cioni
Journal:  Hepat Oncol       Date:  2016-06-10

3.  Clinical practice guideline for image-guided multimode tumour ablation therapy in hepatic malignant tumours.

Authors:  G Z Wang; X H He; Y Wang; L C Xu; H Z Huang; Y H Wang; Z Shen; X D Qu; X Y Ding; J J Yang; W T Li
Journal:  Curr Oncol       Date:  2019-10-01       Impact factor: 3.677

Review 4.  Focal ablation therapy for renal cancer in the era of active surveillance and minimally invasive partial nephrectomy.

Authors:  Serge Ginzburg; Jeffrey J Tomaszewski; Alexander Kutikov
Journal:  Nat Rev Urol       Date:  2017-09-12       Impact factor: 14.432

Review 5.  Hepatocellular carcinoma.

Authors:  Josep M Llovet; Robin Kate Kelley; Augusto Villanueva; Amit G Singal; Eli Pikarsky; Sasan Roayaie; Riccardo Lencioni; Kazuhiko Koike; Jessica Zucman-Rossi; Richard S Finn
Journal:  Nat Rev Dis Primers       Date:  2021-01-21       Impact factor: 52.329

Review 6.  Curative-Intent Therapies in Localized Hepatocellular Carcinoma.

Authors:  Cathal O'Leary; Mary Mahler; Michael C Soulen
Journal:  Curr Treat Options Oncol       Date:  2020-03-19

7.  Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma.

Authors:  Alexander Gerbes; Fabien Zoulim; Herbert Tilg; Jean-François Dufour; Jordi Bruix; Valérie Paradis; Riad Salem; Markus Peck-Radosavljevic; Peter R Galle; Tim F Greten; Jean-Charles Nault; Matias A Avila
Journal:  Gut       Date:  2017-11-17       Impact factor: 23.059

Review 8.  The need for multidisciplinarity in specialist training to optimize future patient care.

Authors:  Alison C Tree; Victoria Harding; Aneel Bhangu; Venkatesh Krishnasamy; Dion Morton; Justin Stebbing; Bradford J Wood; Ricky A Sharma
Journal:  Nat Rev Clin Oncol       Date:  2016-11-29       Impact factor: 66.675

9.  Evolutions in the Management of Hepatocellular Carcinoma over Last 4 Decades: An Analysis from the 100 Most Influential Articles in the Field.

Authors:  Gang Xu; Bao Jin; Xiaomeng Xian; Huayu Yang; Haitao Zhao; Shunda Du; Masatoshi Makuuchi; Timothy M Pawlik; Yilei Mao
Journal:  Liver Cancer       Date:  2021-02-02       Impact factor: 11.740

Review 10.  Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma.

Authors:  Josep M Llovet; Thierry De Baere; Laura Kulik; Philipp K Haber; Tim F Greten; Tim Meyer; Riccardo Lencioni
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-01-28       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.